A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer | Zendy

Keith C. Bible | Zendy; Vera J. Suman | Zendy; Michael E. Menefee | Zendy; Robert C. Smallridge | Zendy; Julian R. Molina | Zendy; William J. Maples | Zendy; Nina J. Karlin | Zendy; Anne M. Traynor | Zendy; Priya Kumar | Zendy; Boon Cher Goh | Zendy; WanTeck Lim | Zendy; Ayoko R. Bossou | Zendy; Crescent R. Isham | Zendy; Kevin Webster | Zendy; Andrea K. Kukla | Zendy; Carolyn Bieber | Zendy; Jill K. Burton | Zendy; Pamela Jo Harris | Zendy; Charles Erlichman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer

Author(s) -

Keith C. Bible,

Vera J. Suman,

Michael E. Menefee,

Robert C. Smallridge,

Julian R. Molina,

William J. Maples,

Nina J. Karlin,

Anne M. Traynor,

Priya Kumar,

Boon Cher Goh,

WanTeck Lim,

Ayoko R. Bossou,

Crescent R. Isham,

Kevin Webster,

Andrea K. Kukla,

Carolyn Bieber,

Jill K. Burton,

Pamela Jo Harris,

Charles Erlichman

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-1520

Subject(s) - pazopanib , anaplastic thyroid cancer , medicine , oncology , thyroid cancer , phases of clinical research , cancer , clinical trial , sunitinib

Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive metastatic differentiated thyroid cancer, prompting its evaluation in anaplastic thyroid cancer (ATC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research